December 13, 2019

N-glycosylation Customization of Rituximab using FastPharming™ system

N-glycosylation is known to affect the biological activity of human therapeutics such as anti-cancer monoclonal antibodies, blood factors, or lysosomal enzymes. Over the last decade, several methods have been developed to enable the engineering of ...

Continue Reading

January 7, 2019

In vivo Glycan Engineering via the Mannosidase I Inhibitor (Kifunensine) Improves Efficacy of Rituximab Manufactured in Nicotiana benthamiana Plants

N-glycosylation has been shown to affect the pharmacokinetic properties of several classes of biologics, including monoclonal antibodies, blood factors, and lysosomal enzymes. In the last two decades, N-glycan engineering has been employed to achieve a ...

Continue Reading

July 9, 2018

Plant-made E2 glycoprotein single-dose vaccine protects pigs against classical swine fever

Classical Swine Fever Virus (CSFV) causes classical swine fever, a highly contagious hemorrhagic fever affecting both feral and domesticated pigs. Outbreaks of CSF in Europe, Asia, Africa and South America had significant adverse impacts on animal ...

Continue Reading

June 14, 2018

Advanced Plant-Based Glycan Engineering

With respect to biomanufacturing, glycosylation is one of the most addressed post-translational modifications, since it is well-known that the attachment of sugar residues efficiently affects protein homogeneity and functionality. Much effort has been ...

Continue Reading

February 7, 2018

Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing
Antibodies and Confer Protection against Viral Challenge in Animal Models

Abstract. Yellow fever (YF) is a viral disease transmitted by mosquitoes and endemic mostly in South America and Africa with 20–50% fatality. All current licensed YF vaccines, including YF-Vax® (Sanofi-Pasteur, Lyon, France) and 17DD-YFV (Bio-Manguinhos, ...

Continue Reading
1 2 3